Adaptimmune Therapeutics (ADAP) - Market capitalization

Market cap: NZ$24.91 Million

As of May 2026 Adaptimmune Therapeutics has a market cap of NZ$24.91 Million. This makes Adaptimmune Therapeutics the world's 10389th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of Adaptimmune Therapeutics from 2015 to 2026

End of year Market Cap

Year	Marketcap	Change
2026	NZ$24.91 M	-0.83%
2025	NZ$25.12 M	-90.61%
2024	NZ$0.26 B	-6.01%
2023	NZ$0.28 B	-24.4%
2022	NZ$0.37 B	-56.07%
2021	NZ$0.85 B	-25.84%
2020	NZ$1.15 B	517.08%
2019	NZ$0.18 B	-79.1%
2018	NZ$0.89 B	1.73%
2017	NZ$0.88 B	112.92%
2016	NZ$0.41 B	-66.82%
2015	NZ$1.24 B

Market capitalization for similar companies or competitors

Name	Marketcap	Market cap differencediff.	Country
uniQure QURE	NZ$2.92 B	11,623.84%	🇳🇱 Netherlands
Novavax NVAX	NZ$2.55 B	10,138.30%	🇺🇸 USA
Exelixis EXEL	NZ$21.57 B	86,492.96%	🇺🇸 USA
Enzo Biochem ENZB	NZ$62.64 M	151.44%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Market capitalization of Adaptimmune Therapeutics (ADAP)

Market cap: NZ$24.91 Million